Tarlatamab combined with chemoimmunotherapy achieved a 71% objective response rate in ES-SCLC, with a median response duration of 11 months. The safety profile was manageable, with grade 3 or 4 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback